Mobile

A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Resp...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004665-33

A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a Prior Course of Interferon Based Therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To compare to control (Group A) (peginterferon alfa-2a [Peg IFN-a-2a] and ribavirin [RBV] for 48 weeks) the proportion of subjects who achieve sustained viral response (SVR, undetectable HCV RNA 24 weeks after completion of treatment) when given telaprevir in combination with: Peg IFN-a-2a and RBV for 24 weeks followed by 24 weeks of Peg IFN a-2a and RBV given alone (Group B); Peg IFN-a-2a for 24 weeks (Group C); Peg IFN-a-2a and RBV for 12 weeks followed by 12 weeks of Peg IFN-a-2a and RBV given alone (Group D).

Critère d'inclusion

  • Hepatitis C virus (HCV) infection

Liens